Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17713974,time of maximum plasma concentration,"Duloxetine is well absorbed, with a median time of maximum plasma concentration at 6 and 4 hours following single and multiple dosing, respectively.",Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713974/),h,6,4454,DB00476,Duloxetine
,17713974,time of maximum plasma concentration,"Duloxetine is well absorbed, with a median time of maximum plasma concentration at 6 and 4 hours following single and multiple dosing, respectively.",Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713974/),h,4,4455,DB00476,Duloxetine
,17713974,apparent oral clearance (CL(ss)/F),"At steady state, the mean apparent oral clearance (CL(ss)/F), mean apparent volume of distribution (V(ss)/F) and mean terminal elimination half-life (t((1/2))) were 86.8 L/h, 1570L and 11 hours, respectively.",Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713974/),[l] / [h],86.8,4456,DB00476,Duloxetine
,17713974,apparent volume of distribution (V(ss)/F),"At steady state, the mean apparent oral clearance (CL(ss)/F), mean apparent volume of distribution (V(ss)/F) and mean terminal elimination half-life (t((1/2))) were 86.8 L/h, 1570L and 11 hours, respectively.",Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713974/),l,1570,4457,DB00476,Duloxetine
,17713974,terminal elimination half-life (t((1/2))),"At steady state, the mean apparent oral clearance (CL(ss)/F), mean apparent volume of distribution (V(ss)/F) and mean terminal elimination half-life (t((1/2))) were 86.8 L/h, 1570L and 11 hours, respectively.",Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713974/),h,11,4458,DB00476,Duloxetine
,17713974,t((1/2)),"The accumulation in duloxetine exposure was estimated to be 50% on multiple dosing compared with single dosing, consistent with the t((1/2)) and dosing interval (24 hours).",Pharmacokinetics and tolerability of duloxetine following oral administration to healthy Chinese subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17713974/),h,24,4459,DB00476,Duloxetine
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,42.8,5359,DB00476,Duloxetine
,18307373,oral bioavailability,"In the presence of fluvoxamine, the oral bioavailability of duloxetine increased from 42.8% to 81.9%.",In vitro and in vivo evaluations of cytochrome P450 1A2 interactions with duloxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18307373/),%,81.9,5360,DB00476,Duloxetine
,18193916,steady-state milk-to-plasma,"The mean steady-state milk-to-plasma duloxetine exposure ratio was 0.25 (90% CI 0.18, 0.35).",Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193916/),,0.25,25370,DB00476,Duloxetine
,18193916,exposure ratio,"The mean steady-state milk-to-plasma duloxetine exposure ratio was 0.25 (90% CI 0.18, 0.35).",Pharmacokinetics of duloxetine in breast milk and plasma of healthy postpartum women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18193916/),,0.25,25371,DB00476,Duloxetine
,33324051,bioavailability,Duloxetine (DLX) is dual serotonin and norepinephrine reuptake inhibitor suffering from limited bioavailability (≈ 40%) due to extensive hepatic metabolism.,"Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),%,40,50571,DB00476,Duloxetine
,33324051,PS,"It had PS of 265.13 ± 9.85 nm, GT of 32 ± 0.05°C, EE% of 98.13 ± 0.50%, and showed controlled release behavior where 33% DLX was released within 6 hrs.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),nm,265.13,50572,DB00476,Duloxetine
,33324051,GT,"It had PS of 265.13 ± 9.85 nm, GT of 32 ± 0.05°C, EE% of 98.13 ± 0.50%, and showed controlled release behavior where 33% DLX was released within 6 hrs.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),°,32,50573,DB00476,Duloxetine
,33324051,EE%,"It had PS of 265.13 ± 9.85 nm, GT of 32 ± 0.05°C, EE% of 98.13 ± 0.50%, and showed controlled release behavior where 33% DLX was released within 6 hrs.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),%,98.13,50574,DB00476,Duloxetine
,33324051,BTE%,"Its BTE% and DTP% were 137.77 and 10.5, respectively, indicating efficient brain targeting after intranasal administration.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),,137.77,50575,DB00476,Duloxetine
,33324051,DTP%,"Its BTE% and DTP% were 137.77 and 10.5, respectively, indicating efficient brain targeting after intranasal administration.","Brain Targeting of Duloxetine HCL via Intranasal Delivery of Loaded Cubosomal Gel: In vitro Characterization, ex vivo Permeation, and in vivo Biodistribution Studies. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33324051/),,10.5,50576,DB00476,Duloxetine
,29016875,occupancy,"Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg.","Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016875/),%,29.7,55445,DB00476,Duloxetine
,29016875,occupancy,"Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg.","Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016875/),%,30.5,55446,DB00476,Duloxetine
,29016875,occupancy,"Norepinephrine transporter occupancy by duloxetine was 29.7% at 20 mg, 30.5% at 40 mg, and 40.0% at 60 mg.","Occupancy of Norepinephrine Transporter by Duloxetine in Human Brains Measured by Positron Emission Tomography with (S,S)-[18F]FMeNER-D2. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29016875/),%,40.0,55447,DB00476,Duloxetine
,33190552,entrapment efficiency,"The entrapment efficiency was in the range of 74.93 to 77.49, respectively, of PLGA and PCL formulation.","Polymer-based prolonged-release nanoformulation of duloxetine: fabrication, characterization and neuropharmacological assessments. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33190552/),,74.93,74446,DB00476,Duloxetine
,29403794,flow rate,"The chromatographic separation was achieved on a C18 column by using a mixture of acetonitrile-5 mM ammonium acetate buffer (83:17, v/v) as the mobile phase at a flow rate of 0.9 mL/min.",A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for duloxetine in human plasma: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403794/),[ml] / [min],0.9,74950,DB00476,Duloxetine
,29403794,run time,A run time of 2.5 min for each sample made it possible to analyze more than 300 plasma samples per day.,A rapid and sensitive liquid chromatography-tandem mass spectrometric assay for duloxetine in human plasma: Its pharmacokinetic application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29403794/),min,2.5,74951,DB00476,Duloxetine
,23771193,AUC(0-infinity),"The mean AUC(0-infinity) was significantly smaller for the postbariatric surgery (PBS) group (646.74 ng × h/mL [SD, 79.70; range, 539.57-791.62], P = 0.017) compared to the nonsurgical control group (1119.91 ng × h/mL [SD, 593.40; range, 415.5-2426.56]).",A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23771193/),[h·ng] / [ml],646.74,81673,DB00476,Duloxetine
,23771193,AUC(0-infinity),"The mean AUC(0-infinity) was significantly smaller for the postbariatric surgery (PBS) group (646.74 ng × h/mL [SD, 79.70; range, 539.57-791.62], P = 0.017) compared to the nonsurgical control group (1119.91 ng × h/mL [SD, 593.40; range, 415.5-2426.56]).",A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23771193/),[h·ng] / [ml],1119.91,81674,DB00476,Duloxetine
,23771193,Tmax,The Tmax was also significantly shorter for the PBS group (2.2 hours) compared to the nonsurgical control group (6 hours; P = 0.005).,A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23771193/),h,2.2,81675,DB00476,Duloxetine
,23771193,Tmax,The Tmax was also significantly shorter for the PBS group (2.2 hours) compared to the nonsurgical control group (6 hours; P = 0.005).,A comparison of duloxetine plasma levels in postbariatric surgery patients versus matched nonsurgical control subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23771193/),h,6,81676,DB00476,Duloxetine
,19539103,methodologic recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,87.22,108120,DB00476,Duloxetine
,19539103,extraction recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,113.75,108121,DB00476,Duloxetine
,19539103,extraction recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,72.81,108122,DB00476,Duloxetine
,19539103,extraction recovery,"The methodologic recovery and extraction recovery ranged from 87.22% to 113.75% and 72.81% to 89.96%, respectively.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),%,89.96,108123,DB00476,Duloxetine
,19539103,C(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],22.46,108124,DB00476,Duloxetine
,19539103,C(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],44.40,108125,DB00476,Duloxetine
,19539103,C(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],60.78,108126,DB00476,Duloxetine
,19539103,AUC(0-60),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],328.64,108127,DB00476,Duloxetine
,19539103,AUC(0-60),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],696.04,108128,DB00476,Duloxetine
,19539103,AUC(0-60),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],1219.33,108129,DB00476,Duloxetine
,19539103,AUC(0-infinity)),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],359.68,108130,DB00476,Duloxetine
,19539103,AUC(0-infinity)),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],733.82,108131,DB00476,Duloxetine
,19539103,AUC(0-infinity)),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],1280.51,108132,DB00476,Duloxetine
,19539103,T(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.83,108133,DB00476,Duloxetine
,19539103,T(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.10,108134,DB00476,Duloxetine
,19539103,T(max),"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.60,108135,DB00476,Duloxetine
,19539103,t1/2,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,12.95,108136,DB00476,Duloxetine
,19539103,t1/2,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,12.81,108137,DB00476,Duloxetine
,19539103,t1/2,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,11.66,108138,DB00476,Duloxetine
,19539103,CL,"The main PK parameters for duloxetine after administration of a single oral dose of 30, 60, and 90 mg were as follows: C(max) = 22.46 (15.15), 44.40 (17.18), and 60.78 (27.84) ng/mL, respectively; AUC(0-60) = 328.64 (203.64), 696.04 (337.82), and 1219.33 (598.29) ng/mL . h(-1); AUC(0-infinity)) = 359.68 (201.01), 733.82 (343.40), and 1280.51 (644.81) ng/mL . h(-1); T(max) = 6.83 (1.99), 6.10 (1.29), and 6.60 (1.58) hours; t1/2 = 12.95 (3.64), 12.81 (2.31), and 11.66 (2.06) hours; CL = 107.90 (53.05), 98.41 (41.98), and 109.58 (52.74) L/hour; and V(d) = 2518.88 (1707.71), 1879.74 (999.09), and 1858.47 (1203.69) L.","Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),,107.90,108139,DB00476,Duloxetine
,19539103,C(ssmax),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],47.33,108140,DB00476,Duloxetine
,19539103,C(ssmm),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],27.92,108141,DB00476,Duloxetine
,19539103,AUC(ss(0-t)),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ml·ng] / [h],407.25,108142,DB00476,Duloxetine
,19539103,C(ssav),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[ng] / [ml],33.94,108143,DB00476,Duloxetine
,19539103,T(max),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,6.36,108144,DB00476,Duloxetine
,19539103,t(1/2),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),h,11.19,108145,DB00476,Duloxetine
,19539103,CL,Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),[l] / [h],83.12,108146,DB00476,Duloxetine
,19539103,V(d),Mean (SD) values for the main PK parameters for duloxetine after administration of multiple doses were as follows: C(ssmax) = 47.33 (16.95) ng/mL; C(ssmm) = 27.92 (9.46) ng/mL; AUC(ss(0-t)) = 407.25 (125.94) ng/mL . h(-1); C(ssav) = 33.94 (13.00) ng/mL; T(max) = 6.36 (0.92) hours; t(1/2) = 11.19 (1.98) hours; CL = 83.12 (28.75) L/hour; and V(d) = 1359.01 (590.06) L.,"Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19539103/),l,1359.01,108147,DB00476,Duloxetine
<,20384393,CL(CR),"For patients with ESRD or severe renal impairment (CL(CR) <30 mL/min), exposures of duloxetine and its metabolites are expected to increase; therefore, duloxetine is not generally recommended for these patients.",Effects of varying degrees of renal impairment on the pharmacokinetics of duloxetine: analysis of a single-dose phase I study and pooled steady-state data from phase II/III trials. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20384393/),,30,116039,DB00476,Duloxetine
,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,50-400,122850,DB00476,Duloxetine
>,21036913,IC(50),"KLYP961 (4-((2-cyclobutyl-1H-imidazo[4,5-b]pyrazin-1-yl)methyl)-7,8-difluoroquinolin-2(1H)-one) inhibits the dimerization, and hence the enzymatic activity of human, primate, and murine iNOS and nNOS (IC(50) values 50-400 nM), with marked selectivity against endothelial nitric-oxide synthase (IC(50) >15,000 nM).","Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),nM,"15,000",122851,DB00476,Duloxetine
≤,21036913,minimal effective dose,KLYP961 also attenuated capsaicin-induced thermal allodynia in rhesus primates in a dose-related manner with a minimal effective dose (≤ 10 mg/kg p.o.) and a greater potency than gabapentin.,"Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21036913/),mg,10,122852,DB00476,Duloxetine
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,35.3,123919,DB00476,Duloxetine
,27207183,Ki,"ZBH2012001 exhibited a moderate affinity to SERTs and NETs (Ki values were 35.3 ± 2.86 and 225 ± 26.0 nM, respectively); it had no effects on the DATs or the 16 other GPCRs or iron channels.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),nM,225,123920,DB00476,Duloxetine
,27207183,absolute bioavailability,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),%,60.5,123921,DB00476,Duloxetine
,27207183,LD50,"The pharmacokinetic evaluation of ZBH2012001 indicated that the absolute bioavailability value was 60.5%, and the acute toxicity test indicated that LD50 of ZBH2012001 was 346 mg/kg.","Antidepressant-like Effects of ZBH2012001, a Novel Potent Serotonin and Norepinephrine Reuptake Inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207183/),[mg] / [kg],346,123922,DB00476,Duloxetine
,20940733,OC(50),Repeat-dose prediction from the indirect model (OC(50)=2.62±0.93 ng/mL) was significantly better (P<0.05) than that from the direct model (OC(50)=2.29±1.11 ng/mL).,Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940733/),[ng] / [ml],2.62,129424,DB00476,Duloxetine
,20940733,OC(50),Repeat-dose prediction from the indirect model (OC(50)=2.62±0.93 ng/mL) was significantly better (P<0.05) than that from the direct model (OC(50)=2.29±1.11 ng/mL).,Prediction of repeat-dose occupancy from single-dose data: characterisation of the relationship between plasma pharmacokinetics and brain target occupancy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20940733/),[ng] / [ml],2.29,129425,DB00476,Duloxetine
,12920170,total recovery of radioactivity,The mean total recovery of radioactivity (+/- S.E.M.) after 312 h was 90.5% (+/-0.4%) with 72.0% (+/-1.1%) excreted in the urine.,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),%,90.5,136272,DB00476,Duloxetine
,12920170,total recovery of radioactivity,The mean total recovery of radioactivity (+/- S.E.M.) after 312 h was 90.5% (+/-0.4%) with 72.0% (+/-1.1%) excreted in the urine.,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ",Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),%,72.0,136273,DB00476,Duloxetine
,12920170,elimination half-life,The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),h,120,136274,DB00476,Duloxetine
,12920170,elimination half-life,The elimination half-life of total radioactivity (120 h) was substantially longer than that of duloxetine (10.3 h).,"Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12920170/),h,10.3,136275,DB00476,Duloxetine
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],47,143268,DB00476,Duloxetine
,21366359,maximum plasma concentration (C(max)),Duloxetine achieves a maximum plasma concentration (C(max)) of approximately 47 ng/mL (40 mg twice-daily dosing) to 110 ng/mL (80 mg twice-daily dosing) approximately 6 hours after dosing.,Duloxetine: clinical pharmacokinetics and drug interactions. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),[ng] / [ml],110,143269,DB00476,Duloxetine
,21366359,elimination half-life,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),h,10-12,143270,DB00476,Duloxetine
,21366359,volume of distribution,The elimination half-life of duloxetine is approximately 10-12 hours and the volume of distribution is approximately 1640 L.,Duloxetine: clinical pharmacokinetics and drug interactions. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21366359/),l,1640,143271,DB00476,Duloxetine
,22235148,ED(50),"Duloxetine exhibited selectivity for occupancy of SERT over NET in rat spinal cord with ED(50) values of 1 and 9 mg/kg, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[mg] / [kg],1,154892,DB00476,Duloxetine
,22235148,ED(50),"Duloxetine exhibited selectivity for occupancy of SERT over NET in rat spinal cord with ED(50) values of 1 and 9 mg/kg, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[mg] / [kg],9,154893,DB00476,Duloxetine
,22235148,EC(50),Corresponding EC(50) values for the inhibition of SERT and NET based on unbound duloxetine spinal cord concentrations were 0.5 and 8 nM.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),nM,0.5,154894,DB00476,Duloxetine
,22235148,EC(50),Corresponding EC(50) values for the inhibition of SERT and NET based on unbound duloxetine spinal cord concentrations were 0.5 and 8 nM.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),nM,8,154895,DB00476,Duloxetine
,22235148,plasma EC(50),"Duloxetine inhibited SERT and NET in rat spinal cord with a plasma EC(50) of 2.95 and 59.0 ng/ml, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],2.95,154896,DB00476,Duloxetine
,22235148,plasma EC(50),"Duloxetine inhibited SERT and NET in rat spinal cord with a plasma EC(50) of 2.95 and 59.0 ng/ml, respectively.",Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],59.0,154897,DB00476,Duloxetine
,22235148,plasma,Similar plasma EC(50) values for the inhibition of SERT (2.29-3.7 ng/ml) have been reported from human PET studies.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],2.29-3.7,154898,DB00476,Duloxetine
,22235148,EC(50),Similar plasma EC(50) values for the inhibition of SERT (2.29-3.7 ng/ml) have been reported from human PET studies.,Prediction of human serotonin and norepinephrine transporter occupancy of duloxetine by pharmacokinetic/pharmacodynamic modeling in the rat. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22235148/),[ng] / [ml],2.29-3.7,154899,DB00476,Duloxetine
,29615471,Ki,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,4.81,166369,DB00476,Duloxetine
,29615471,Ki,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,6.72,166370,DB00476,Duloxetine
,29615471,IC50,"In the present study, we synthesized a series of novel 3-(benzo[d][1,3]dioxol-4-yloxy)-3-arylpropyl amine derivatives, among which compound H05 was identified as a lead, exhibiting potent inhibitory effects on both serotonin (Ki = 4.81 nM) and norepinephrine (NE) (Ki = 6.72 nM) transporters and moderate 5-HT2A antagonist activity (IC50 = 60.37 nM).","Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29615471/),nM,60.37,166371,DB00476,Duloxetine
,32957789,flow rate,"The analytes of interest and internal standard (duloxetine (DUL)) were extracted from 100 μL of plasma with solid-phase extraction on an Oasis HLB cartridge followed by the separation with gradient elution with water containing 0.1% formic acid and acetonitrile on an Agilent Eclipse Plus ODS (4.6 × 100 mm, 3.5 μm) column at flow rate 0.2 mL min-1.","Toxicity Profile, Pharmacokinetic, and Drug-Drug Interaction Study of Citalopram and Sertraline Following Oral Delivery in Rat: An LC-MS/MS Method for the Simultaneous Determination in Plasma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32957789/),[ml] / [min],0.2,168143,DB00476,Duloxetine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],40,175115,DB00476,Duloxetine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],37,175116,DB00476,Duloxetine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],22,175117,DB00476,Duloxetine
,18043474,steady state serum concentration,"In serum samples from 37 patients treated with 30 to 120 mg per day for at least 7 days, the mean steady state serum concentration of duloxetine was 40 ng/mL, the median was 37 ng/mL, and the 25th and 75th percentiles were 22 and 55 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],55,175118,DB00476,Duloxetine
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],33,175119,DB00476,Duloxetine
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],43,175120,DB00476,Duloxetine
,18043474,serum concentrations,"At 60, 90, and 120 mg/day, the mean +/- SD serum concentrations were 33+/-22.0, 43+/-22.2, and 48+/-17.0 ng/mL, respectively.",Measurement of duloxetine in blood using high-performance liquid chromatography with spectrophotometric detection and column switching. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18043474/),[ng] / [ml],48,175121,DB00476,Duloxetine
,10664922,oral clearance,"The mean oral clearance, apparent volume of distribution, and half-life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12.5 h (range: 9.2 to 19.1 h), respectively.","Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664922/),[l] / [h],114,186115,DB00476,Duloxetine
,10664922,apparent volume of distribution,"The mean oral clearance, apparent volume of distribution, and half-life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12.5 h (range: 9.2 to 19.1 h), respectively.","Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664922/),l,1943,186116,DB00476,Duloxetine
,10664922,half-life,"The mean oral clearance, apparent volume of distribution, and half-life values were 114 L/h (range: 44 to 218 L/h), 1943 L (range: 803 to 3531 L), and 12.5 h (range: 9.2 to 19.1 h), respectively.","Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10664922/),h,12.5,186117,DB00476,Duloxetine
,17904920,flow rate,"The mobile phase consisting of a mixture of acetonitrile and 5mM ammonium acetate (45:55, v/v, pH 3.5) was delivered at a flow rate of 0.3 ml/min.",Determination of duloxetine in human plasma by liquid chromatography with atmospheric pressure ionization-tandem mass spectrometry and its application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17904920/),[ml] / [min],0.3,202718,DB00476,Duloxetine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.973,209164,DB00476,Duloxetine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.136,209165,DB00476,Duloxetine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.041,209166,DB00476,Duloxetine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,38,209167,DB00476,Duloxetine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,53,209168,DB00476,Duloxetine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,75,209169,DB00476,Duloxetine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,2.72,209170,DB00476,Duloxetine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,1.22,209171,DB00476,Duloxetine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.794,209172,DB00476,Duloxetine
,29427845,zeta potential,"Optimized microemulsion (D1) showed spherical droplets with mean diameter of 35.40 ± 3.11 nm, PDI of 0.170 and zeta potential values of -25.8 mV.",Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427845/),m,25.8,215515,DB00476,Duloxetine
greater,29427845,transmit,"Formulation showed good transmittance (greater than 99%), viscosity (0.205 Pa s) and refractive index (1.43 ± 0.01).",Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427845/),%,99,215516,DB00476,Duloxetine
,29427845,viscosity,"Formulation showed good transmittance (greater than 99%), viscosity (0.205 Pa s) and refractive index (1.43 ± 0.01).",Duloxetine loaded-microemulsion system to improve behavioral activities by upregulating serotonin and norepinephrine in brain for the treatment of depression. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29427845/),pa·s,0.205,215517,DB00476,Duloxetine
,24810241,radiolabeling,"The radiolabeling efficiency of DLX and DLX-NLC was found to be 98.41 ± 0.96 and 98.87 ± 0.82 after 30 min, respectively.",Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810241/),,98.41,225368,DB00476,Duloxetine
,24810241,radiolabeling,"The radiolabeling efficiency of DLX and DLX-NLC was found to be 98.41 ± 0.96 and 98.87 ± 0.82 after 30 min, respectively.",Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24810241/),,98.87,225369,DB00476,Duloxetine
≈,29172829,oral bioavailability,Duloxetine suffers from reduced oral bioavailability (≈50%) due to hepatic metabolism.,Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172829/),%,50,227314,DB00476,Duloxetine
,29172829,percentage relative bioavailability,The percentage relative bioavailability of DH from F2 was found to be 296.39%.,Formulation and optimization of duloxetine hydrochloride buccal films: in vitro and in vivo evaluation. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29172829/),%,296.39,227315,DB00476,Duloxetine
,24989060,CL/F,"Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79.7 L/h, 1,200 L, and 10.4 h, respectively.",Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989060/),[l] / [h],79.7,241113,DB00476,Duloxetine
,24989060,V d/F,"Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79.7 L/h, 1,200 L, and 10.4 h, respectively.",Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989060/),l,"1,200",241114,DB00476,Duloxetine
,24989060,half-life (t 1/2),"Typical values of CL/F, V d/F, and half-life (t 1/2) at 60 mg/day of duloxetine were 79.7 L/h, 1,200 L, and 10.4 h, respectively.",Pharmacokinetics of orally administered duloxetine in children and adolescents with major depressive disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24989060/),h,10.4,241115,DB00476,Duloxetine
,15726876,apparent clearance,"Duloxetine apparent clearance was significantly lower (24 vs 160 l/h, p < 0.05) and AUC values were substantially higher (775 vs 268 ng x (h/ml) in cirrhotic compared to healthy subjects.",Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726876/),[l] / [h],24,251705,DB00476,Duloxetine
,15726876,apparent clearance,"Duloxetine apparent clearance was significantly lower (24 vs 160 l/h, p < 0.05) and AUC values were substantially higher (775 vs 268 ng x (h/ml) in cirrhotic compared to healthy subjects.",Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726876/),[l] / [h],160,251706,DB00476,Duloxetine
,15726876,AUC,"Duloxetine apparent clearance was significantly lower (24 vs 160 l/h, p < 0.05) and AUC values were substantially higher (775 vs 268 ng x (h/ml) in cirrhotic compared to healthy subjects.",Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726876/),[h·ng] / [ml],775,251707,DB00476,Duloxetine
,15726876,AUC,"Duloxetine apparent clearance was significantly lower (24 vs 160 l/h, p < 0.05) and AUC values were substantially higher (775 vs 268 ng x (h/ml) in cirrhotic compared to healthy subjects.",Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726876/),[h·ng] / [ml],268,251708,DB00476,Duloxetine
,15726876,half-life,The half-life of duloxetine was about three times longer (47.8 vs 13.5 h) in cirrhotic than in healthy subjects (p < 0.05).,Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726876/),h,47.8,251709,DB00476,Duloxetine
,15726876,half-life,The half-life of duloxetine was about three times longer (47.8 vs 13.5 h) in cirrhotic than in healthy subjects (p < 0.05).,Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15726876/),h,13.5,251710,DB00476,Duloxetine
,16303903,Half-life,"Half-life and volume of distribution are 12 hours and 1640 L, respectively.",Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303903/),h,12,252091,DB00476,Duloxetine
,16303903,volume of distribution,"Half-life and volume of distribution are 12 hours and 1640 L, respectively.",Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16303903/),l,1640,252092,DB00476,Duloxetine
,31268632,Ratio of,We obtained good predictions for the dextromethorphan-duloxetine interaction (Ratio of predicted over observed area under the curve (AUC) ratio (Rpred/obs ) 1.38-1.43).,Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,1.38-1.43,257178,DB00476,Duloxetine
,31268632,area under the curve (AU,We obtained good predictions for the dextromethorphan-duloxetine interaction (Ratio of predicted over observed area under the curve (AUC) ratio (Rpred/obs ) 1.38-1.43).,Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,1.38-1.43,257179,DB00476,Duloxetine
,31268632,Rpred/obs,"Despite an approximately twofold underprediction of the dextromethorphan-paroxetine interaction, an Rpred/obs of 0.71 was obtained for the effect of genotype on the area under the curve ratio.",Physiologically-Based Pharmacokinetic Modeling for the Prediction of CYP2D6-Mediated Gene-Drug-Drug Interactions. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31268632/),,0.71,257180,DB00476,Duloxetine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,298.1,266332,DB00476,Duloxetine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,154.1,266333,DB00476,Duloxetine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,376.2,266334,DB00476,Duloxetine
,30648587,m/z,"Quantification was performed in multiple-reaction-monitoring mode with the ion transitions m/z 384.4 → 253.2 for quetiapine, m/z 298.1 → 154.1 for duloxetine and m/z 376.2 → 165.2 for IS (haloperidol), respectively.",A rapid LC-MS/MS method for simultaneous determination of quetiapine and duloxetine in rat plasma and its application to pharmacokinetic interaction study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30648587/),,165.2,266335,DB00476,Duloxetine
